Literature DB >> 27072959

Significance of cyclooxygenase-2 elevation in middle cerebral artery for patients with hemorrhagic moyamoya disease.

Jian-Jian Zhang1,2, Zhong-Wei Xiong1,2, Sheng Wang2, Shou-Jia Sun2, Hao Wang2, Xiao-Lin Wu2, Long Wang2, Hua-Qiu Zhang2, Chao You2, Yu Wang2, Jin-Cao Chen3,4.   

Abstract

The etiology and pathogenesis of moyamoya disease (MMD) remain elusive. Some inflammatory proteins, such as cyclooxygenase (COX)-2, are believed to be implicated in the development of MMD. So far, the relationship between COX-2 and MMD is poorly understood and reports on the intracranial vessels of MMD patients are scanty. In this study, tiny pieces of middle cerebral artery (MCA) and superficial temporal artery (STA) from 13 MMD patients were surgically harvested. The MCA and STA samples from 5 control patients were also collected by using the same technique. The expression of COX-2 was immunohistochemically detected and the average absorbance (A) of positively-stained areas was measured. High-level COX-2 expression was found in all layers of the MCA samples from all 5 hemorrhagic MMD patients, while positive but weak expression of COX-2 was observed only in the endothelial layer of the MCA samples from most ischemic MMD patients (6/8, 75%). The average A values of COX-2 in the hemorrhagic MMD patients were substantially higher than those in their ischemic counterparts (t=4.632, P=0.001). There was no significant difference in the COX-2 expression among the "gender" groups, or "radiographic grade" groups, or "lesion location" groups (P>0.05 for all). The COX-2 expression was detected neither in the MCA samples from the controls nor in all STA specimens. Our results suggested that COX-2 was up-regulated in the MCA of MMD patients, especially in hemorrhagic MMD patients. We are led to speculate that COX-2 may be involved in the pathogenesis of MMD and even contribute to the hemorrhagic stroke of MMD patients.

Entities:  

Keywords:  COX-2; hemorrhage; inflammation; middle cerebral artery; moyamoya disease

Mesh:

Substances:

Year:  2016        PMID: 27072959     DOI: 10.1007/s11596-016-1563-1

Source DB:  PubMed          Journal:  J Huazhong Univ Sci Technolog Med Sci        ISSN: 1672-0733


  20 in total

Review 1.  Moyamoya disease: current concepts and future perspectives.

Authors:  Satoshi Kuroda; Kiyohiro Houkin
Journal:  Lancet Neurol       Date:  2008-11       Impact factor: 44.182

2.  Proposal for a new grading of Moyamoya disease in adult patients.

Authors:  M Czabanka; P Peña-Tapia; G A Schubert; F L Heppner; P Martus; P Horn; P Schmiedek; P Vajkoczy
Journal:  Cerebrovasc Dis       Date:  2011-05-11       Impact factor: 2.762

3.  Abnormal cerebrovascular network related to the internal cartoid arteries.

Authors:  A Nishimoto; S Takeuchi
Journal:  J Neurosurg       Date:  1968-09       Impact factor: 5.115

4.  Moyamoya disease--a review.

Authors:  J Suzuki; N Kodama
Journal:  Stroke       Date:  1983 Jan-Feb       Impact factor: 7.914

5.  Increase in prostaglandin E(2) production by interleukin-1beta in arterial smooth muscle cells derived from patients with moyamoya disease.

Authors:  M Yamamoto; M Aoyagi; N Fukai; Y Matsushima; K Yamamoto
Journal:  Circ Res       Date:  1999-11-12       Impact factor: 17.367

6.  Epidemiological features of moyamoya disease in Japan: findings from a nationwide survey.

Authors:  K Wakai; A Tamakoshi; K Ikezaki; M Fukui; T Kawamura; R Aoki; M Kojima; Y Lin; Y Ohno
Journal:  Clin Neurol Neurosurg       Date:  1997-10       Impact factor: 1.876

7.  Expression of cellular retinoic acid-binding protein-I (CRABP-I) in the cerebrospinal fluid of adult onset moyamoya disease and its association with clinical presentation and postoperative haemodynamic change.

Authors:  Jin Sue Jeon; Jun Hyong Ahn; Youn-Joo Moon; Won-Sang Cho; Young-Je Son; Seung-Ki Kim; Kyu-Chang Wang; Jae Seung Bang; Hyun-Seung Kang; Jeong Eun Kim; Chang Wan Oh
Journal:  J Neurol Neurosurg Psychiatry       Date:  2013-11-29       Impact factor: 10.154

8.  Regulation of cyclooxygenase-2 expression in aortic smooth muscle cells.

Authors:  J A Rimarachin; J A Jacobson; P Szabo; J Maclouf; C Creminon; B B Weksler
Journal:  Arterioscler Thromb       Date:  1994-07

9.  Role of transforming growth factor-beta1 in the pathogenesis of moyamoya disease.

Authors:  M Hojo; M Hoshimaru; S Miyamoto; W Taki; I Nagata; M Asahi; N Matsuura; R Ishizaki; H Kikuchi; N Hashimoto
Journal:  J Neurosurg       Date:  1998-10       Impact factor: 5.115

10.  Smooth muscle cell proliferation and localization of macrophages and T cells in the occlusive intracranial major arteries in moyamoya disease.

Authors:  J Masuda; J Ogata; C Yutani
Journal:  Stroke       Date:  1993-12       Impact factor: 7.914

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.